Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Remibrutinib

f899e40c-36d9-5159-bb34-76e0b142a283 · FDA Phase III Trials · targets BTK

Remibrutinib

MeasuredReference

Remibrutinib targets BTK, BMX_ETK. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

BTKBMX_ETK

Top hallmarks

  • tumor promoting inflammation572
  • proliferation513
  • evading apoptosis491

Top pathways disrupted

  • pi3k akt mtor signaling1.1k
  • allograft rejection987
  • mitotic spindle855

Resistance landscape — Remibrutinib

MeasuredReference

5 known oncogenic variants exist on Remibrutinib's top targets — see detail for inhibition impact.

Open in new tab